To determine whether Nrf2 activation and the subsequent redox adaptation, a strategy frequently used by cancer cells to survive and become resistant to several anticancer agents, might be related to the response of PC3 cells to TM treatment, we exposed PC3 cells to GRP78/BiP-antibody and investigated the effects of TM. This evidence concerns the gene NFE2L2 and cancer.